Riskpilot← Back to searchSign inGet full accessFLAVIA MEDISIN AS
ASActiveOrg 821041252Grønliveien 35, 1056 OsloMedical specialists activities · NACE 8622Est. 20182 employees
Revenue 2025
NOK 6,8M
+6% vs 2024
EBITDA margin
21.5%
+34% vs 2024
Equity ratio
1.6%
Financial strength
Net profit 2025
NOK 1,1M
+29% vs 2024
| Revenue | NOK 6,8M | +6% |
| EBITDA | NOK 1,5M | +34% |
| Net profit | NOK 1,1M | +29% |
| Total assets | NOK 1,9M | +23% |
| Equity | NOK 31K | +1% |
| Employees | 2 | — |
Legal name
FLAVIA MEDISIN AS
Org number
821041252
Legal form
Aksjeselskap
NACE code
8622 · Medical specialists activities
Founded
21. juni 2018
Share capital
NOK 30 000
Employees
2 (FTE)
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Legetjenester, avtalespesialist barnesykdommer.
Address
Grønliveien 35, 1056 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 5 967 | 6 450 | 6 547 | 6 409 | 6 802 |
| Staff expenses | −1 897 | −2 060 | −1 970 | −1 941 | −1 900 |
| EBITDA | 993 | 1 101 | 1 124 | 1 089 | 1 464 |
| Depreciation & amort. | −63 | −58 | −20 | −37 | −111 |
| EBIT | 929 | 1 043 | 1 104 | 1 052 | 1 353 |
| Net financials | 0 | 0 | −1 | −0 | 1 |
| Profit before tax | 929 | 1 043 | 1 103 | 1 052 | 1 353 |
| Tax | 208 | 231 | 244 | 232 | 298 |
| Net profit | 722 | 811 | 860 | 821 | 1 055 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 1 494 | 1 641 | 978 | 1 583 | 1 946 |
| Equity | 31 | 42 | 202 | 30 | 31 |
| Long-term debt | 0 | 0 | 0 | 3 | 1 |
| Short-term debt | 1 464 | 1 599 | 777 | 1 549 | 1 914 |
| Total debt | 1 464 | 1 599 | 777 | 1 552 | 1 915 |
EBITDA margin
21.5%
This company
15.8%
Market median
+36% vs market
20212025
Equity ratio
1.6%
This company
38.2%
Market median
-96% vs market
20212025
Return on equity
3442.5%
This company
18.4%
Market median
+18609% vs market
20212025
Net profit margin
15.5%
This company
8.1%
Market median
+91% vs market
20212025
Asset turnover
3.50×
This company
1.12×
Market median
+212% vs market
20212025
Debt / equity
62.47×
This company
0.62×
Market median
-9976% vs market
20212025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
FO Chief Executive Officer | Chief Executive Officer | 2018 |
| Name | Role | Member since |
|---|---|---|
| Current (5) | ||
| Board of Directors | 2018 | |
| Board of Directors | 2018 | |
| Board of Directors | 2018 | |
| Board of Directors | 2018 | |
| Board of Directors | 2018 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of FLAVIA MEDISIN AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Frøydis Olafsen | Chief Executive Officer | 0 companies |
| Magnus Olafsen Melbye | Board of Directors | 0 companies |
| Lars Melbye | Board of Directors | 0 companies |
| Jens Olafsen Melbye | Board of Directors | 0 companies |
| Anders Olafsen Melbye | Board of Directors | 0 companies |
| Hans Olafsen Melbye | Board of Directors | 0 companies |